Home » Stocks » PSTI

Pluristem Therapeutics, Inc. (PSTI)

Stock Price: $7.89 USD 0.02 (0.25%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $7.95 +0.06 (0.76%) Jan 20, 6:53 PM
Market Cap 202.25M
Revenue (ttm) 23,000
Net Income (ttm) -30.50M
Shares Out 25.54M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $7.89
Previous Close $7.87
Change ($) 0.02
Change (%) 0.25%
Day's Open 8.08
Day's Range 7.80 - 8.19
Day's Volume 546,484
52-Week Range 2.89 - 12.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 weeks ago

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therap...

GlobeNewsWire - 1 month ago

HAIFA, Israel, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...

Seeking Alpha - 1 month ago

Pluristem's CLI Phase III trial interim results should be published soon. Results are critical and might define the fate of the company.

GlobeNewsWire - 2 months ago

HAIFA, Israel, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...

GlobeNewsWire - 3 months ago

HAIFA, Israel, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological prod...

Seeking Alpha - 3 months ago

Two new sample breakout stocks for Week 43 with better than 10% short-term upside potential. Now up an average +241.2% YTD.

Other stocks mentioned: CAT, CSCO, ECOM, HON, INTC, JNJ, MCD, MRK, NKE, PG, WMT
Zacks Investment Research - 3 months ago

Investors need to pay close attention to Pluristem Therapeutics (PSTI) stock based on the movements in the options market lately.

GlobeNewsWire - 3 months ago

Reports internal efficacy and safety data from first cohort Reports internal efficacy and safety data from first cohort

GlobeNewsWire - 3 months ago

HAIFA, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( Nasdaq:PSTI ) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ther...

GlobeNewsWire - 4 months ago

HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...

GlobeNewsWire - 4 months ago

HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...

Zacks Investment Research - 5 months ago

Pluristem (PSTI) completes enrollment in the phase I study in patients with complete hematopoietic recovery following hematopoietic cell transplantation in the United States and Israel.

GlobeNewsWire - 5 months ago

Top line efficacy results expected Q1 2021 Top line efficacy results expected Q1 2021

GlobeNewsWire - 5 months ago

HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...

GlobeNewsWire - 7 months ago

HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...

GlobeNewsWire - 7 months ago

HAIFA, Israel, June 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...

Zacks Investment Research - 7 months ago

Is (PSTI) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 8 months ago

Pluristem Therapeutics: The Search For An ARDS Treatment, And Whether Its Growth Will Continue

Zacks Investment Research - 8 months ago

Is (PSTI) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 8 months ago

Update is provided in advance of the company’s recruitment of first patient for its phase II Covid-19 study Update is provided in advance of the company’s recruitment of first patient for its ...

GlobeNewsWire - 8 months ago

HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ...

GlobeNewsWire - 8 months ago

HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological th...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor in Pluristem Therapeutics Inc. (PSTI).

Zacks Investment Research - 8 months ago

Does Pluristem (PSTI) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 8 months ago

• Elaborating on agreement terms and tranches schedule • Provides update on cash position and clinical program

GlobeNewsWire - 8 months ago

HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- 

The Motley Fool - 8 months ago

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Other stocks mentioned: ATHX, MESO
The Motley Fool - 8 months ago

The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.

GlobeNewsWire - 8 months ago

EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020 EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020

Seeking Alpha - 9 months ago

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: ORGS, TDOC
Zacks Investment Research - 9 months ago

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

Zacks Investment Research - 9 months ago

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Other stocks mentioned: ATHX, GILD, JNJ, MESO, PFE, REGN
GlobeNewsWire - 9 months ago

HAIFA, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological ...

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Pluristem (PSTI) stock based on the movements in the options market lately.

Benzinga - 9 months ago

Pluristem Therapeutics (NASDAQ: PSTI) shares are trading higher on Tuesday, after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients ...

GlobeNewsWire - 9 months ago

HAIFA, Israel, April 07, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...

GlobeNewsWire - 9 months ago

HAIFA, Israel, March 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biologica...

GlobeNewsWire - 9 months ago

HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological pr...

GlobeNewsWire - 10 months ago

HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 20 20 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company deve...

GlobeNewsWire - 11 months ago

HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell thera...

GlobeNewsWire - 11 months ago

HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological...

GlobeNewsWire - 1 year ago

Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to trea...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Pluristem Therapeutics.

GlobeNewsWire - 1 year ago

Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture Multinational study ...

GlobeNewsWire - 1 year ago

HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...

Zacks Investment Research - 1 year ago

Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

HAIFA, Israel, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...

GlobeNewsWire - 1 year ago

Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET Data readout from second cohort of hematological study will be pr...

GlobeNewsWire - 1 year ago

HAIFA, Israel, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy...

About PSTI

Pluristem Therapeutics, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in pa... [Read more...]

Industry
Biotechnology
Founded
2001
CEO
Yaky Yanay
Employees
146
Stock Exchange
NASDAQ
Ticker Symbol
PSTI
Full Company Profile

Financial Performance

In 2020, PSTI's revenue was $23,000, a decrease of -57.41% compared to the previous year's $54,000. Losses were -$29.15 million, -17.43% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for PSTI stock is "Buy." The 12-month stock price forecast is 8.60, which is an increase of 9.00% from the latest price.

Price Target
$8.60
(9.00% upside)
Analyst Consensus: Buy